MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Ovarian cancer diagnosis and treatment
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,301 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,301 works in the cohort · of 4,299,418page 22 of 47

Labels cover 7 of 2,301 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,301 of 2,301 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).
Shannon N. Westin, Kathleen N. Moore, Els Van Nieuwenhuysen, Amit M. Oza, Linda Mileshkin, Aikou Okamoto +5 more
2020· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
10
citations
affno abstractunlabeled
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS)
Felicia Roncolato, Rachel O’Connell, Florence Joly, Anne Lanceley, Felix Hilpert, Luke Buizen +12 more
2019· article· en· Gynecologic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
10
citations
affno abstractunlabeled
The Abnormal Ovary
Kalesha Hack, Phyllis Glanc
2019· review· en· Obstetrics and Gynecology Clinics of North America· Medicine
machine prediction:candidate · noneconsensus · none
9
citations
affno abstractunlabeled
Current Academic Clinical Trials in Ovarian Cancer
Edward L. Trimble, Michael J. Birrer, William J. Hoskins, Christian Marth, Ray A. Petryshyn, Michael Quinn +2 more
2010· review· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
9
citations
affno abstractunlabeled
833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer
David M. O’Malley, Debra L. Richardson, I. Vergote, Lucy Gilbert, Cesar M. Castro, Diane Provencher +5 more
2020· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
9
citations

How this was built: Screen · Findings · About